Congenital Heart Defects Clinical Trial
Official title:
A Feasibility Study to Evaluate the Safety and Short-term Effectiveness of Implantation of Transcatheter Pulmonary Valve (TPV) for the Treatment of Congenital Heart Disease With Pulmonary Valve Disease
The purpose of this study is to evaluate the safety and short-term effectiveness of implantation of Transcatheter Pulmonary Valve (TPV) for the treatment of congenital heart disease with pulmonary valve disease.
Diverse congenital heart diseases involving the pulmonary artery, such as Tetralogy of Fallot (TOF) with or without pulmonary atresia, or transposition of the great arteries with pulmonary stenosis, require implantation of an artificial conduit between the right ventricle and the pulmonary artery(PA). Because these conduits finally degenerate and result in pulmonary regurgitation and/or stenosis and progressive right ventricle (RV) dilation and eventual failure, patients need repetitive surgery for conduit revision. Transcatheter pulmonary valve implantation (TPVI) is a less invasive alternative to surgery in patients with dysfunctional right ventricular outflow tract (RVOT). TPV is a large-diameter (up to 28 mm) self-expandable stent with a relatively low profile from a nitinol wire backbone with valve leaflets made from porcine pericardial tissue. The TPV is indicated for use in patients with previous undergone replacement of bioprosthetic valve or conduit due to either pulmonary valve atresia, stenosis, regurgitation or a combination of them and present with dysfunctional RVOT requiring treatment for severe pulmonary regurgitation and/or RVOT conduit obstruction. Consecutive subject data should be collected at discharge, 1, 3, 6 month, and 1-5 years post TPV implantation. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01671566 -
Interval Training in Adults With Congenital Heart Disease a Randomized Trial
|
N/A | |
Recruiting |
NCT01421030 -
Outcomes in Patients and Their Closest Relatives Treated for Congenital Heart Disease With Catheter Based or Surgical Techniques
|
Phase 0 | |
Withdrawn |
NCT00981591 -
Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01567579 -
An Evaluation of Routine Developmental Follow-Up in Infants and Children With Congenital Heart Disease
|
||
Terminated |
NCT00208676 -
Using Tissue Doppler/Synchronization to Determine Heart Function in Children With Congenital Heart Disease
|
N/A | |
Completed |
NCT01941576 -
Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot
|
N/A | |
Completed |
NCT01475357 -
Intestinal Function in Neonates With Complex Congenital Heart Disease
|
N/A | |
Active, not recruiting |
NCT01227096 -
Randomized Controlled Trial of the Effects of Electroacupuncture Preconditioning in Children Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT00397514 -
Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery
|
N/A | |
Completed |
NCT01201486 -
Use of Color Doppler in Routine Examination of Fetal Heart in Second Trimester
|
N/A | |
Completed |
NCT02232399 -
Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease?
|
Phase 2 | |
Completed |
NCT05191654 -
Investigation of Cardiopulmonary Parameters, Motor Development and Muscle Strength in DS With and Without CHD
|
||
Recruiting |
NCT06267859 -
Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children
|
Early Phase 1 | |
Completed |
NCT02320669 -
Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
|
Phase 3 | |
Completed |
NCT01489475 -
Plasma Angiopoietin Levels in Children Following Cardiopulmonary Bypass
|
N/A | |
Withdrawn |
NCT00579358 -
Molecular Basis of Congenital Heart Defects
|
||
Recruiting |
NCT01196182 -
Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)
|
||
Recruiting |
NCT03822442 -
MRI to Predict Rejection and Failure in Transplant and Cardiomyopathy Patients
|
||
Recruiting |
NCT04382573 -
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.
|
||
Completed |
NCT00450684 -
Cardiac Resynchronization Therapy in Congenital Heart Defects
|
Phase 2/Phase 3 |